Cabaletta Bio News and Activities

Cabaletta Bio is a company listed under the stock ticker CABA (US).

Acquisition, funding and merger involving Cabaletta Bio.

• Cabaletta Bio has just announced a $150 Million fundraising (posted on May 12 2026).

View the org chart displaying its 32 main executives

Most searched biographies at Cabaletta Bio

• Steven Nichtberger, Chairman and Chief Executive Officer
• Mark Simon, Director
• Scott Brun, Director

Popular executive movements at Cabaletta Bio

• Steve Gavel has joined the company as Chief Commercial Officer  (posted on October 16 2025).

Create your alert
to follow the executive moves at Cabaletta Bio.

Cabaletta Bio has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Archimed Group has acquired Esperion Therapeutics (posted on July 14 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 14 2026).
• MindRank has just announced a $52 Million fundraising (posted on July 14 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Cabaletta Bio

• Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
• Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
• Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
• Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
• Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
• Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
• Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
• Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
• Cabaletta Bio Announces 2026 Strategic Priorities
• View more press releases Close

Social media about Cabaletta Bio

• Cabaletta Bio on Wikipedia, Google News & Yahoo Finance
• Cabaletta Bio on LinkedIn, X (Twitter) & YouTube